# Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

> **NCT04293393** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Spanish Breast Cancer Research Group** · enrollment: 200 (actual)

## Conditions studied

- Early Breast Cancer

## Interventions

- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Taxane
- **DRUG:** Letrozole
- **DRUG:** Abemaciclib
- **DRUG:** LHRH Analogue

## Key facts

- **NCT ID:** NCT04293393
- **Lead sponsor:** Spanish Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-02
- **Primary completion:** 2023-06-21
- **Final completion:** 2033-02-28
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2026-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04293393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04293393, "Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04293393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*